Opportunities for More Tailored Approaches to Genotoxicity Testing and Carcinogenicity Strategy for Oligonucleotide Therapeutics: Outcome of an Industry SurveyJoel D. Parry, Yi Yan Yang, Tod A. Harper et al.|Nucleic Acid Therapeutics|2025Cited by 2
An Industry Perspective on Key Considerations for the ICH S13 Guidance: Nonclinical Safety Evaluations of Oligonucleotide-Based TherapeuticsJennifer D. Sisler, Tod A. Harper, Yi Yang et al.|International Journal of Toxicology|2026Cited by 1